尼妥珠单抗联合同步放化疗治疗局部晚期鳞状细胞肺癌的2期随机试验
本研究为单中心、开放标签、随机2期试验,纳入不可切除III期鳞状细胞肺癌患者,比较同步放化疗联合或不联合尼妥珠单抗的疗效与安全性。结果显示联合组与单纯放化疗组的总生存和无进展生存相似,但联合组脑转移风险显著降低,且耐受性良好。
要点
- 尼妥珠单抗联合同步放化疗未显著改善局部晚期鳞状细胞肺癌的总生存和无进展生存。
- 联合组脑转移风险显著低于单纯放化疗组,校正亚分布风险比为0.099。
- 联合组≥3级肺炎和食管炎发生率与对照组相似,且无≥2级皮肤毒性。
核心结论
- 尼妥珠单抗联合同步放化疗耐受性良好,总生存和无进展生存与单纯放化疗相似,但脑转移风险显著降低。
研究设计与样本
- 前瞻性、单中心、开放标签、随机2期试验,纳入不可切除III期鳞状细胞肺癌患者126例随机,122例纳入分析(联合组57例,单纯放化疗组65例)。
- 放疗剂量为65 Gy/5周,同步多西他赛和顺铂化疗,联合组每周静脉输注尼妥珠单抗200 mg。
- 主要终点为总生存,次要终点包括无进展生存、客观缓解率、失败模式和治疗相关毒性。
主要发现
- 联合组中位总生存24.9个月,单纯放化疗组23.5个月(P = .655)。
- 联合组中位无进展生存12.1个月,单纯放化疗组13.7个月(P = .968)。
- 联合组脑转移风险显著降低,校正亚分布风险比0.099(95%置信区间0.012-0.81;P = .031)。
- 两组≥3级肺炎(P = .894)和食管炎(P = .974)发生率相似,联合组无≥2级皮肤毒性。
关键数值与推荐
- 联合组脑转移校正亚分布风险比为0.099(95%置信区间0.012-0.81;P = .031)。
- 总生存组间比较P = .655,无进展生存组间比较P = .968。
- ≥3级肺炎组间比较P = .894,≥3级食管炎组间比较P = .974。
临床怎么用
- 对于不可切除III期鳞状细胞肺癌,尼妥珠单抗联合同步放化疗可作为耐受性良好的治疗选择,尤其需关注脑转移风险降低的潜在获益。
- 联合方案未显著改善总生存和无进展生存,临床决策需结合患者个体情况。
局限性
- 本研究为单中心、开放标签、2期随机试验,样本量有限,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The study aimed to evaluate the efficacy and safety of concurrent chemoradiation therapy (CCRT) combined with nimotuzumab in patients with unresectable stage III squamous cell lung cancer (SqCLC). METHODS AND MATERIALS: A prospective, single-center, open-label, randomized phase 2 trial was performed in patients with unresectable stage III SqCLC. Patients were randomized to receive 65 Gy thoracic radiation over 5 weeks concurrent with docetaxel and cisplatin or the same CCRT regimen combined with 200 mg of nimotuzumab (NIMO-CCRT), administered weekly by intravenous infusion. The primary endpoint was overall survival. The secondary endpoints were progression-free survival, objective response rate, failure patterns, and treatment-related toxicity. RESULTS: From August 2015 to June 2020, 126 patients with SqCLC were randomized. Four patients withdrew consent before the start of treatment, and 122 patients were included for analysis, including 57 in the NIMO-CCRT group and 65 in the CCRT group. The median OS was 24.9 months in the NIMO-CCRT group and 23.5 months in the CCRT group (P = .655). The median PFS was 12.1 months in the NIMO-CCRT group and 13.7 months in the CCRT group (P = .968). The NIMO-CCRT group had a significantly lower risk of brain metastasis, with adjusted subdistribution hazard ratio of 0.099 (95% confidence interval, 0.012-0.81; P = .031). The incidence of grade ≥3 pneumonitis (P = .894) and esophagitis (P = .974) was similar between the 2 arms. There was no grade 2 or higher skin toxicity in NIMO-CCRT group. CONCLUSIONS: The coincident application of nimotuzumab with CCRT was well tolerated for locally advanced SCCL. The NIMO-CCRT group had an OS and PFS similar to that in the CCRT group, but a lower risk of brain metastasis. Further investigations are warranted.
引用
- Qiu B, Wang D, Li Q, et al. Concurrent Chemoradiation Therapy With or Without Nimotuzumab in Locally Advanced Squamous Cell Lung Cancer: A Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys. 2021. PMID: 34229051. doi:10.1016/j.ijrobp.2021.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。